Sarepta Therapeutics at a Crossroads — Gene Therapy Pioneer Faces Commercial and Financial Headwinds

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. The company generates revenue primarily from the sale of four approved DMD treatments: Exondys 51 (eteplirsen), Vyondys 53 (golodirsen), Amondys 45 (casimersen), and Elevidys (delandistrogene moxeparvovec), the latter being the first approved gene therapy for DMD. Customers include specialty pharmacies, hospitals, and government payers across the U.S. and select international markets. As of the latest data, Sarepta has a market capitalization of $2.1B, with 105.63M shares outstanding and 101.04M shares in the public float.

• Near-Term (Next 12 Months): Revenue growth will depend on the commercial execution of Elevidys, which is approved for ambulatory DMD patients aged 4-5 years. Expanding label indications to older patients and non-ambulatory populations could drive meaningful uptake. However, competitive entry from other gene therapies and exon-skipping agents may limit market share gains.
• Medium-Term (2-5 Years): The pipeline for LGMD and other indications offers diversified growth. If positive clinical data emerge, Sarepta could establish a leadership position in multiple rare neuromuscular diseases. Additionally, international expansion, particularly in Europe and Japan, could unlock new revenue streams, though regulatory and reimbursement hurdles remain.

Note: Figures are illustrative estimates based on company trends and analyst consensus; actual results may vary.

Revenue growth is projected to accelerate as Elevidys penetrates the eligible DMD population and as exon-skipping therapies maintain a steady base. However, operating margins remain deeply negative due to high R&D spending and commercial costs. The path to profitability hinges on scaling Elevidys manufacturing and achieving label expansions. The company's cash position is expected to decline, potentially necessitating debt or equity financing, which could dilute shareholders given the current market cap of $2.1B.

The global DMD therapeutics market is estimated at approximately $3-4B annually, with growth driven by gene therapies and novel exon-skipping agents. Sarepta competes with:

• Pfizer (PFE): Developing its own mini-dystrophin gene therapy (fordadistrogene movaparvovec), which may reach the market within 2-3 years, posing a direct competitive threat.
• Solid Biosciences (SLDB): Focused on gene therapies for DMD and other neuromuscular diseases, though earlier-stage.
• Roche (RHHBY): Partner with Sarepta on Elevidys for ex-U.S. commercialization, providing capital and distribution but also sharing economics.

Sarepta's competitive advantage lies in its approved portfolio and manufacturing expertise, but the high short interest (30.69% of float) suggests the market doubts its ability to maintain a dominant position against well-funded competitors.

Discounted Cash Flow (DCF): Using a conservative WACC of 10% and a terminal growth rate of 3%, with projected free cash flows turning positive in FY2028, the DCF-derived intrinsic value is approximately $18.50 per share, implying modest downside from the current price of $19.72. Sensitivity analysis shows that a 2% change in WACC alters the valuation by ±$4.00 per share.

Comparable Company Multiples:

Sarepta trades at a discount to large-cap peers on EV/Sales, reflecting its profitability challenges and competitive risks. However, the low EV/Sales multiple may be justified given the binary nature of pipeline events and the need for additional capital.

• Clinical and Regulatory Setbacks: Failure of Elevidys in broader DMD populations or negative data from the LGMD program could destroy significant value, given the high expectations embedded in the stock.
• Commercial Reimbursement and Competition: Payer restrictions on high-cost gene therapies and the entry of Pfizer's competitor product could limit revenue growth and compress margins.
• Funding and Dilution Risk: With a market cap of $2.1B and negative EPS, the company may need to raise capital via equity issuance, diluting existing shareholders. The 30.69% short interest indicates that many investors expect such an event.
• Manufacturing and Supply Chain: Gene therapy production is complex; any scale-up issues or quality control failures could disrupt supply and harm patient trust.
• Key Person and Intellectual Property: Dependence on a small number of scientific leaders and the risk of IP litigation could impair the company's ability to operate.